Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Faeth Therapeutics, Inc. - Common Stock (NQ:FTH)

12.68 -9.37 (-42.49%)
Delayed Quote Updated: 4:00 PM EST, Nov 9, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Faeth Therapeutics, Inc. - Common Stock

US Session Top Movers: FISN, XHLD, TLS Lead Gainers; ZURA, SOC, PLCE Lead Losers ↗
Via Chartmill
Top Movers Today: MF Gains 89.56%, ZURA Falls 72.98% ↗
Via Chartmill
US Gap-Up and Gap-Down Movers for the Nov. 9, 2026 Session ↗
Via Chartmill
Premarket Movers on Nov. 9, 2026: Small-Cap Gainers and Losers ↗
Via Chartmill
News headline image
Faeth Reports Positive Preliminary Phase 2 Topline Results from the PIK-201 Trial Evaluating PIKTOR in Combination with Paclitaxel in Patients with Advanced Endometrial Cancer
From Faeth Therapeutics, Inc.
Via Business Wire
After-Hours Market Movers: Gainers and Decliners From Today's U.S. Session ↗
Via Chartmill
News headline image
Faeth to Report PIK-201 Phase 2 Data and Host Virtual Event on November 9, 2026
From Faeth Therapeutics, Inc.
Via Business Wire
News headline image
Faeth Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Faeth Therapeutics, Inc.
Via Business Wire
News headline image
Faeth Therapeutics Reports Third Quarter 2026 Financial Results and Operational Updates
From Faeth Therapeutics
Via Business Wire
News headline image
Faeth Appoints Adam Schayowitz, Ph.D., MBA, Head of Research and Development at Zymeworks, to Board of Directors
From Faeth Therapeutics, Inc.
Via Business Wire
News headline image
Faeth Presents Updated Preclinical Data at ESMO, including First-Ever Head-to-Head Characterization of PIKTOR against Gedatolisib
From Faeth Therapeutics
Via Business Wire
News headline image
Faeth Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Faeth Therapeutics, Inc.
Via Business Wire
News headline image
Faeth to Present Preclinical Data on PIKTOR in HR+/HER2- Breast Cancer Models at ESMO 2026
From Faeth Therapeutics, Inc.
Via Business Wire
News headline image
Sensei Biotherapeutics Highlights PIKTOR Strategy Ahead of Endometrial Trial Readout ↗
Faeth Therapeutics outlined its clinical strategy for PIKTOR, an oral combination designed to inhibit the PI3K/AKT/mTOR, or PAM, pathway at multiple points, during an analyst and investor event. The... 
Via MarketBeat
News headline image
Faeth Therapeutics Appoints Karen Vousden, Ph.D., to Board of Directors
From Faeth Therapeutics, Inc.
Via Business Wire
News headline image
Faeth Therapeutics to Host Virtual KOL Event on Multi-Nodal Inhibition for the Treatment of Endometrial Cancer on October 6, 2026
From Faeth Therapeutics, Inc.
Via Business Wire
News headline image
Faeth Therapeutics to Participate in Upcoming September Investor Conferences
From Faeth Therapeutics
Via Business Wire
News headline image
Faeth Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Faeth Therapeutics, Inc.
Via Business Wire
News headline image
Faeth Therapeutics Announces FDA Grant of Fast Track Designation for PIKTOR Plus Paclitaxel in Biomarker-Selected Advanced Endometrial Cancer
From Faeth Therapeutics
Via Business Wire
News headline image
Faeth Therapeutics Strengthens Executive Team with Senior Leadership Appointments
From Faeth Therapeutics, Inc.
Via Business Wire
News headline image
Faeth Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Faeth Therapeutics, Inc.
Via Business Wire
News headline image
Faeth Therapeutics to Present PK/PD Modeling That Informed PIKTOR Dose Selection in Ongoing FTH-PIK-201 Trial at Upcoming Scientific Conference
From Faeth Therapeutics
Via Business Wire
News headline image
Faeth Therapeutics Reports Second Quarter 2026 Financial Results and Operational Updates
From Faeth Therapeutics
Via Business Wire
News headline image
Faeth Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Faeth Therapeutics, Inc.
Via Business Wire
News headline image
Faeth Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Faeth Therapeutics, Inc.
Via Business Wire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.